Surrozen, Inc./DE cotiza a 24.76 USD y tiene una capitalización bursátil de $291M. En los últimos 12 meses ha facturado $12M con un margen de flujo de caja libre del -873.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cor…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-2.10 | $-4.63 | $-9.62 | $-3.60 |
| Estimado | $-1.26 | $-0.72 | $-1.24 | $-1.17 |
| Sorpresa | -66.7% | -543.1% | -675.8% | -207.7% |
| Métrica | SRZN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1210.6% | -38.6% | -1172.0% |
| Net Margin | -6960.8% | -33.6% | -6927.2% |
| FCF Margin | -873.5% | -13.9% | -859.6% |
| ROE | — | -40.4% | — |
| ROA | -245.2% | -32.0% | -213.1% |
| Current Ratio | 9.22 | 2.84 | +6.38 |
| Debt / Equity | — | 0.28 | — |